A carregar...
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma
Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death (PD)-1 receptor. Common cutaneous adverse side effects of PD-1 inhibitors include maculopapular rash, pruritus, vitiligo, and lichenoid skin and mucosal reactions. Here, we describe a man in his sixties with metas...
Na minha lista:
| Publicado no: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5533648/ https://ncbi.nlm.nih.gov/pubmed/28132411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.15354 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|